ClinicalTrials.gg
CompletedNCT03537274Updated Apr 9, 2019Results posted

Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)

A Phase 2/3 interventional study of PEG-Intron and Interferon Alfa-2B in Hepatitis C, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-09.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Registered 20 years 9 months after the study started (first participant enrolled Aug 1997, registered May 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,224
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing peginterferon alfa-2b in Hepatitis C — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C.

Enrollment
3rd of 23
1,224 · median 102
Started
1997
the only one that year
Phase 2/3
2 of 23
none open now
Registered
23rd of 23
by date
Lead sponsor
8 of 23
Merck Sharp & Dohme LLC

Among the 23 studies testing peginterferon alfa-2b in Hepatitis C, this one is the 3rd largest by enrollment, is the only one that started in 1997, is one of 2 in phase 2/3, and was the 23rd registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 23 studies testing peginterferon alfa-2b in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies testing peginterferon alfa-2b in Hepatitis C as a file.
02

Study summary

This study will determine the efficacy of PEG-Intron (SCH 54031) in participants with chronic Hepatitis C virus (HCV) infection who have not been previously treated with interferon. Participants are randomized to receive one of three doses of PEG-Intron (0.5, 1.0, and 1.5 mg/kg) or Interferon Alfa-2B for 48 weeks. The primary objective of this study is to evaluate the efficacy of PEG-Intron (compared to Interferon Alfa-2B) with respect to response based on loss of detectable HCV ribonucleic acid (HCV-RNA) and normalization of alanine transaminase (ALT) level after 24 weeks of therapy and at 24 weeks of follow-up.

03

Conditions studied

  • Hepatitis C

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be serum positive for virus.
  • Have liver within 1 year prior to entry, with a pathology report confirming a histological diagnosis consistent with chronic hepatitis.
  • Have one abnormal historic at least 6 months prior to screening, with elevated ALT at entry.
  • Have compensated liver disease, testing negative for and serum surface antigen (HBsAg) at entry.
  • If male or female of , be practicing adequate during treatment.

Exclusion criteria

Exclusion Criteria:

  • Be female who is currently pregnant or nursing.
  • Have prior treatment with any interferon.
  • Have suspected to alpha interferon.
  • Have participated in any other clinical trial within 30 days of entry
  • Have received treatment with any drug within 30 days of entry.
  • Have received prior treatment for hepatitis with any other antiviral or immunomodulatory drug within the previous 2 years.
  • Have any other cause for the liver disease other than chronic including but not limited to: co-infection with virus; Hemochromatosis; alpha-1 antitrypsin deficiency; Wilson's disease; hepatitis; alcoholic liver disease; obesity-induced liver disease; and drug-related liver disease.
  • Have hemophilia or any other condition that would prevent the participant from having a liver , including anticoagulant therapy.
  • Have hemoglobinopathies (e.g., Thalassemia)
  • Have evidence of advanced liver disease such as history or presence of ascites, bleeding varices, spontaneous encephalopathy.
  • Have received organ transplants.
  • Have a preexisting psychiatric condition, especially severe depression, or a history of severe psychiatric disorder, such as major psychoses, suicidal ideation and/or attempt.
  • Have central nervous system trauma or active seizure disorders requiring medication.
  • Have significant cardiovascular dysfunction within the past 6 months (e.g., angina, congestive heart failure, recent myocardial infarction, severe hypertension or significant arrhythmia).
  • Have poorly controlled diabetes mellitus.
  • Have chronic pulmonary disease (e.g., ).
  • Have immunologically mediated disease (e.g., inflammatory bowel disease [Crohn's disease, ulcerative colitis], rheumatoid arthritis, idiopathic thrombocytopenia purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, clinical cryoglobulinemia with vasculitis).
  • Have any medical condition requiring, or likely to require during the course of the study, chronic systemic administration of .
  • Have history of substance abuse, such as alcohol, intravenous drugs and inhaled drugs.
  • Have retinal abnormalities.
  • Be unable to abstain from the consumption of alcohol.
  • Have any other condition which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in and completing the protocol.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,224 participants (actual)

Study arms

  • Experimental
    PEG-Intron, 0.5 mg/kg

    PEG-Intron administered once weekly (QW) for 48 weeks at 0.5 mg/kg by subcutaneous (SC) injection.

    Biological: PEG-Intron

  • Experimental
    PEG-Intron, 1.0 mg/kg

    PEG-Intron administered QW for 48 weeks at 1.0 mg/kg by SC injection.

    Biological: PEG-Intron

  • Experimental
    PEG-Intron, 1.5 mg/kg

    PEG-Intron administered QW for 48 weeks at 1.5 mg/kg by SC injection.

    Biological: PEG-Intron

  • Active comparator
    Interferon Alfa-2b

    Interferon Alfa-2b administered three times per week (TIW) for 48 weeks at 3 million international units (MIU) by SC injection.

    Biological: Interferon Alfa-2B

Interventions

  • BiologicalPEG-Intron

    PEG-Intron is administered QW for 48 weeks by SC injection at 0.5, 1.0, and 1.5 mg/kg body weight. Body weight obtained at the baseline visit is used to calculate dosing.

    Also known as: SCH 54031

  • Interferon alfa-2b is administered TIW for 48 weeks by SC injection at 3 MIU regardless of participant body weight.

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving Responder Status at 24 Weeks of Treatment

    The number of participants achieving responder status at 24 weeks of treatment was assessed. A participant was classified as a responder if, at 24 weeks of treatment, they met both of the following criteria: 1) HCV-Ribonucleic Acid (RNA) negative (defined as \<100 copies/mL serum by quantitative polymerase chain reaction \[qPCR\] assay); and 2) alanine transaminase (ALT) level normal.

    Time frame: Up to 24 weeks

  2. Number of Participants Achieving Sustained Responder Status at 24 Weeks of Follow-up

    The number of participants achieving sustained responder status at 24 weeks of follow-up was assessed. A participant was classified as a sustained responder if, at 24 weeks of follow-up, they met both of the following criteria: 1) HCV-RNA negative (defined as \<100 copies/mL serum by qPCR assay); and 2) ALT level normal.

    Time frame: Up to 72 weeks (up to 48 weeks treatment and 24 weeks follow-up)

07

Results

Posted Apr 9, 2019
Limitations and caveats
Adverse Event (AE) Preferred Terms were converted from WHO-ART dictionary to the MedDRA version 21.0

Participant flow

In total, 1224 participants with chronic Hepatitis C virus (HCV) infection were randomized, with 1219 receiving study treatment.

Participant flow — Overall Study
MilestonePEG-Intron, 0.5 mg/kgPEG-Intron, 1.0 mg/kgPEG-Intron, 1.5 mg/kgInterferon Alfa-2b
Started315298304307
Treated315297304303
Completed255229228231
Not completed60697676

Outcome measures

PrimaryNumber of Participants Achieving Responder Status at 24 Weeks of Treatment

The number of participants achieving responder status at 24 weeks of treatment was assessed. A participant was classified as a responder if, at 24 weeks of treatment, they met both of the following criteria: 1) HCV-Ribonucleic Acid (RNA) negative (defined as \<100 copies/mL serum by quantitative polymerase chain reaction \[qPCR\] assay); and 2) alanine transaminase (ALT) level normal.

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants Achieving Responder Status at 24 Weeks of Treatment
ParticipantsPEG-Intron, 0.5 mg/kgPEG-Intron, 1.0 mg/kgPEG-Intron, 1.5 mg/kgInterferon Alfa-2b
Number of Participants Achieving Responder Status at 24 Weeks of Treatment80879059
Statistical analysis
  • PEG-Intron, 0.5 mg/kg vs Interferon Alfa-2b · Chi-squared · p = 0.078
  • PEG-Intron, 1.0 mg/kg vs Interferon Alfa-2b · Chi-squared · p = 0.005
  • PEG-Intron, 1.5 mg/kg vs Interferon Alfa-2b · Chi-squared · p = 0.004
PrimaryNumber of Participants Achieving Sustained Responder Status at 24 Weeks of Follow-up

The number of participants achieving sustained responder status at 24 weeks of follow-up was assessed. A participant was classified as a sustained responder if, at 24 weeks of follow-up, they met both of the following criteria: 1) HCV-RNA negative (defined as \<100 copies/mL serum by qPCR assay); and 2) ALT level normal.

Time frame:
Up to 72 weeks (up to 48 weeks treatment and 24 weeks follow-up)
Reported as:
Count of participants · Participants
Number of Participants Achieving Sustained Responder Status at 24 Weeks of Follow-up
ParticipantsPEG-Intron, 0.5 mg/kgPEG-Intron, 1.0 mg/kgPEG-Intron, 1.5 mg/kgInterferon Alfa-2b
Number of Participants Achieving Sustained Responder Status at 24 Weeks of Follow-up52706937
Statistical analysis
  • PEG-Intron, 0.5 mg/kg vs Interferon Alfa-2b · Chi-squared · p = 0.128
  • PEG-Intron, 1.0 mg/kg vs Interferon Alfa-2b · Chi-squared · p = <0.001
  • PEG-Intron, 1.5 mg/kg vs Interferon Alfa-2b · Chi-squared · p = <0.001

Adverse events

Collected over Up to 72 weeks (up to 48 weeks treatment and 24 weeks of follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PEG-Intron, 0.5 mg/kg1/315 (0.3%)37/315 (11.7%)306/315 (97.1%)
PEG-Intron, 1.0 mg/kg0/297 (0%)32/297 (10.8%)291/297 (98%)
PEG-Intron, 1.5 mg/kg0/304 (0%)31/304 (10.2%)296/304 (97.4%)
Interferon Alfa-2b2/303 (0.7%)29/303 (9.6%)293/303 (96.7%)
Most frequent serious events
Showing 10 of 104
Most frequent serious events
EventPEG-Intron, 0.5 mg/kgPEG-Intron, 1.0 mg/kgPEG-Intron, 1.5 mg/kgInterferon Alfa-2b
Facial paralysisNervous system disorders1/3153/2970/3040/303
Suicidal ideationPsychiatric disorders3/3152/2972/3041/303
ThrombocytopeniaBlood and lymphatic system disorders0/3152/2970/3040/303
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/3152/2970/3040/303
Musculoskeletal disorderMusculoskeletal and connective tissue disorders0/3150/2970/3042/303
VertigoEar and labyrinth disorders0/3150/2972/3040/303
PneumoniaInfections and infestations0/3151/2972/3040/303
Suicide attemptPsychiatric disorders0/3150/2972/3040/303
HypertensionVascular disorders0/3150/2972/3040/303
Spinal disorderMusculoskeletal and connective tissue disorders0/3151/2972/3040/303
Most frequent other events
Showing 10 of 53
Most frequent other events
EventPEG-Intron, 0.5 mg/kgPEG-Intron, 1.0 mg/kgPEG-Intron, 1.5 mg/kgInterferon Alfa-2b
HeadacheNervous system disorders192/315200/297195/304177/303
FatigueGeneral disorders160/315164/297159/304170/303
MyalgiaMusculoskeletal and connective tissue disorders111/315107/297135/304114/303
ChillsGeneral disorders106/315120/297133/30499/303
Injection site erythemaGeneral disorders135/315120/297122/30447/303
PyrexiaGeneral disorders96/315124/297127/30486/303
AlopeciaSkin and subcutaneous tissue disorders64/31568/297104/30467/303
ArthralgiaMusculoskeletal and connective tissue disorders78/31571/29786/30473/303
NauseaGastrointestinal disorders73/31583/29783/30464/303
Influenza like illnessGeneral disorders57/31566/29776/30459/303

Baseline characteristics

Includes all randomized participants receiving ≥1 dose of study treatment.

Age, Continuous
Age, Continuous(Years)PEG-Intron, 0.5 mg/kgPEG-Intron, 1.0 mg/kgPEG-Intron, 1.5 mg/kgInterferon Alfa-2bTotal
Mean43.1 ± 9.443.7 ± 9.542.9 ± 8.742.6 ± 9.243.1 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)PEG-Intron, 0.5 mg/kgPEG-Intron, 1.0 mg/kgPEG-Intron, 1.5 mg/kgInterferon Alfa-2bTotal
Female13010911496449
Male185188190207770
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 1997 to primary completion in Jul 1999, 23 months.

Results were first posted in Apr 2019, 19 years 8 months after primary completion.

Of 14 phase 2/3 interventional studies under Hepatitis C, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 51. This study's 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2018
First posted
May 25, 2018
StartActual
Aug 5, 1997
Primary completionActual
Jul 23, 1999
CompletionActual
Jul 23, 1999
Results first posted
Apr 9, 2019
Last update
Apr 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03537274
Responsible party
Sponsor
First posted
May 25, 2018
Start date
Aug 5, 1997
Primary completion
Jul 23, 1999
Completion
Jul 23, 1999
Results posted
Apr 9, 2019
Last update
Apr 9, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2b

Start the discussion